Sierra Oncology, Inc.
SRRA evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- momelotinib (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SRRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 1 clinical trial for Sierra Oncology, Inc..
Run Sierra Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sierra Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Sierra Oncology, Inc.'s lead drug candidate?
Sierra Oncology, Inc.'s most advanced tracked candidate is momelotinib (Phase 3) for myelofibrosis.
Who is the CEO of Sierra Oncology, Inc.?
Stephen G. Dilly is the chief executive officer of Sierra Oncology, Inc. (SRRA).
What therapeutic areas does Sierra Oncology, Inc. focus on?
Sierra Oncology, Inc. develops therapies across Oncology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.